NCT06892639: An ongoing trial by Castle Creek Biosciences, LLC.
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06892639 |
|---|---|
| Title | Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 27, 2025 |
| Completion date | Sept. 30, 2027 |
| Required reporting date | Sept. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |